Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
Conditions: Acute Ischemic Stroke; Acute Renal Injury Interventions: Drug: Conestat alfa (Ruconest®); Drug: NaCl 0.9%) Sponsors: University Hospital, Basel, Switzerland; Swiss National Science Foundation; Pharming Technologies B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials